ACADIA PHARMACEUTICALS INC. financials

ACAD CIK 0001070494

Source: EDGAR filings · Built 2026-06-02T02:13:24Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 105.15M 157.20M 16.65M -114.03M -126.78M -143.75M
EBITDA 116.57M 246.68M -67.83M -221.57M -167.09M -283.65M
Working Capital 785.00M 543.45M 361.87M 382.31M 521.75M 611.65M
Net Debt -125.51M -267.59M -131.45M -52.85M -83.00M -276.48M
Gross Margin 91.69% 91.46% 94.27% 98.03% 97.76% 97.69%
Operating Margin 9.78% 24.10% -10.10% -43.23% -35.20% -64.87%
Net Margin 36.49% 23.64% -8.44% -41.76% -34.67% -63.74%
Return on Equity (ROE) 31.86% 30.90% -14.19% -53.94% -31.04% -44.91%
Return on Assets (ROA) 25.00% 19.07% -8.18% -36.74% -23.98% -35.98%
Current Ratio 3.83× 2.38× 2.42× 4.04× 6.43× 6.77×
Debt-to-Equity 0.04× 0.07× 0.13× 0.15× 0.12× 0.08×
Effective Tax Rate -181.49% 12.25% -20.08% -1.19% -0.21% -0.22%
Cash Conversion Ratio 0.28× 0.70× -0.27× 0.53× 0.75× 0.48×
Accruals Ratio 0.18× 0.06× -0.10× -0.17× -0.06× -0.19×
SBC % of Revenue 4.87% 7.00% 9.14% 13.19% 13.14% 19.11%
CapEx Coverage 23.42× 301.57× 334.04× -112.00× -17.95×
Free Cash Flow Per Share $0.62 $0.94 $0.10 $-0.71 $-0.79 $-0.91

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 11.61× 13.49×
P/FCF 43.16× 19.42× 308.17×
FCF Yield 2.32% 5.15% 0.32%
EV / EBITDA 37.95× 11.32×
P/S 4.25× 3.19× 7.10× 4.99× 7.76× 19.32×
P/B 3.71× 4.17× 11.94× 6.44× 6.95× 13.61×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.07B 957.80M 726.44M 517.24M 484.14M 441.75M
Revenues 726.44M 517.24M 484.14M 441.75M
Cost of Goods and Services Sold 89.00M 81.84M 41.64M 10.17M 19.14M 10.21M
Gross Profit 684.80M 507.07M 473.30M 431.54M
Research and Development Expense 328.80M 303.25M 351.62M 361.57M 239.41M 319.13M
Selling, General and Administrative Expense 548.89M 488.43M 406.56M 369.09M 396.03M 388.66M
Operating Income (Loss) 104.81M 230.79M -73.38M -223.60M -170.44M -286.59M
Income Tax Expense (Benefit) -252.10M 31.62M 10.25M 2.53M 351.00K 611.00K
Net Income (Loss) Attributable to Parent 391.00M 226.45M -61.29M -215.97M -167.87M -281.58M
Earnings Per Share, Basic $2.32 $1.37 $-0.37 $-1.34 $-1.05 $-1.79
Weighted Average Number of Shares Outstanding, Basic 168.36M 165.72M 163.82M 161.68M 160.49M 157.33M
Earnings Per Share, Diluted $2.30 $1.36 $-0.37 $-1.34 $-1.05 $-1.79
Weighted Average Number of Shares Outstanding, Diluted 169.92M 166.36M 163.82M 161.68M 160.49M 157.33M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 177.69M 319.59M 188.66M 114.85M 147.44M 326.03M
Assets, Current 1.06B 938.32M 616.13M 507.94M 617.82M 717.62M
Assets 1.56B 1.19B 748.96M 587.81M 700.12M 782.62M
Liabilities, Current 277.11M 394.87M 254.25M 125.63M 96.07M 105.97M
Liabilities 336.81M 454.96M 317.20M 187.40M 159.23M 155.61M
Stockholders' Equity Attributable to Parent 1.23B 732.79M 431.75M 400.41M 540.89M 627.01M
Common Stock, Shares, Outstanding 170.31M 166.71M 164.65M 162.06M 161.01M 159.64M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 109.84M 157.72M 16.70M -114.03M -125.66M -136.17M
Payments to Acquire Property, Plant, and Equipment 4.69M 523.00K 50.00K 0 1.12M 7.59M
Net Cash Provided by (Used in) Investing Activities -302.56M -30.54M 32.00M 73.24M -71.10M 192.51M
Net Cash Provided by (Used in) Financing Activities 49.88M 6.84M 25.13M 8.20M 18.16M 81.00M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ACAD CIK 0001070494), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

EME

EMCOR Group, Inc.

NTB

The Bank of N.T. Butterfield & Son Limited

WLFC

WILLIS LEASE FINANCE CORP